Long-Term Efficacy of Anti-Tumor Necrosis Factor Agents in Pediatric Luminal Crohn's Disease: A Systematic Review of Real-World Evidence Studies
Open Access
- 1 January 2020
- journal article
- review article
- Published by The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition in Pediatric Gastroenterology, Hepatology & Nutrition
- Vol. 23 (2) , 121-131
Abstract
To determine the long-term efficacy of the anti-tumor necrosis factor (TNF) agents, infliximab (IFX) and adalimumab (ADA), in pediatric luminal Crohn's disease (CD) by performing a systematic literature review. An electronic search was performed in Medline, Embase, and the Cochrane Library from inception to September 26, 2019. Eligible studies were cohort studies with observation periods that exceeded 1 year. Studies that reported time-to-event analyses were included. Events were defined as discontinuation of anti-TNF therapy for secondary loss of response. We extracted the probabilities of continuing anti-TNF therapy 1, 2, and 3 years after initiation. In total, 2,464 papers were screened, 94 were selected for full text review, and 13 studies (11 on IFX, 2 on ADA) met our eligibility criteria for inclusion. After 1 year, 83-97% of patients were still receiving IFX therapy. After 2 and 3 years the probability of continuing IFX therapy decreased to 67-91% and 61-85%, respectively. In total, 5 of the 11 studies subgrouped by concomitant medication consistently showed that the probabilities of continuing IFX therapy in patients with prolonged immunomodulator use were higher than those in patients on IFX monotherapy. This review of real-world evidence studies confirms the long-term therapeutic benefit of IFX therapy in diverse cohorts of children with luminal CD. Moreover, it supports the view that combination therapy with an immunomodulator prolongs the durability of IFX therapy in patients who previously failed to recover following first-line therapy. The limited number of time-to-event studies in patients on ADA prevented us from drawing definite conclusions about its long-term efficacy.Keywords
This publication has 24 references indexed in Scilit:
- Concomitant Therapy with Immunomodulator Enhances Infliximab Durability in Pediatric Inflammatory Bowel DiseaseInflammatory Bowel Diseases, 2017
- Infliximab Dosing Strategies and Predicted Trough Exposure in Children With Crohn DiseaseJournal of Pediatric Gastroenterology and Nutrition, 2016
- Identifying Patients at High Risk of Loss of Response to Infliximab Maintenance Therapy in Paediatric Crohn’s DiseaseJournal of Crohn's and Colitis, 2016
- Infliximab “Top‐Down” Strategy is Superior to “Step‐Up” in Maintaining Long‐Term Remission in the Treatment of Pediatric Crohn DiseaseJournal of Pediatric Gastroenterology and Nutrition, 2015
- Adalimumab Therapy in Children With Crohn Disease Previously Treated With InfliximabJournal of Pediatric Gastroenterology and Nutrition, 2015
- Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's diseaseJournal of Crohn's and Colitis, 2014
- Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in Pediatric Crohnʼs DiseaseAmerican Journal of Gastroenterology, 2009
- Long-term outcome of maintenance infliximab therapy in children with Crohnʼs diseaseInflammatory Bowel Diseases, 2009
- Practical methods for incorporating summary time-to-event data into meta-analysisTrials, 2007
- Induction and Maintenance Infliximab Therapy for the Treatment of Moderate-to-Severe Crohn’s Disease in ChildrenGastroenterology, 2007